Current status and prospects of immunotherapy for locally advanced nasopharyngeal carci-noma
Nasopharyngeal carcinoma(NPC)is a squamous cell carcinoma arising from the nasopharyngeal epi-thelium,which is associated with Epstein-Barr virus(EBV)infection and is most common in southern China.Im-munotherapy,particularly immune checkpoint inhibitors(ICIs),provides favorable efficacy with a good safety profile in a variety of solid tumors,including recurrent or metastatic NPC(R/M-NPC).In addition,immuno-therapy has made new breakthroughs in the treatment of locally advanced NPC,and many clinical studies are un-derway.Based on previously reported results,this study presents a comprehensive overview of the advances and challenges by introducing the basic principles and the current status of immunotherapy in NPC,with the expecta-tion that it will serve as a reference for clinical practice in the future.
programmed cell death protein 1immunotherapyclinical trialnasopharyngeal carcinoma
万方数据
维普
